These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 32763273)

  • 1. Response to comment on 'Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma'.
    Sun N; Zhang C; He J
    Cancer Lett; 2020 Dec; 494():5-6. PubMed ID: 32763273
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on 'Clinical significance and inflammatory landscapes of a novel recurrence associated immune signature in early-stage lung adenocarcinoma'.
    Chen D; Wu X; Chen Y; Chen C
    Cancer Lett; 2020 Dec; 494():17. PubMed ID: 32781014
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma.
    Zhang C; Zhang Z; Zhang G; Zhang Z; Luo Y; Wang F; Wang S; Che Y; Zeng Q; Sun N; He J
    Cancer Lett; 2020 Jun; 479():31-41. PubMed ID: 32201203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reverse engineering a predictive signature characterized by proliferation, DNA damage, and immune escape from stage I lung adenocarcinoma recurrence.
    Yao J; Xue X; Qu D; Westphalen CB; Ge Y; Zhang L; Li M; Gao T; Chandrakesan P; Vega KJ; Peng J; An G; Weygant N
    Acta Biochim Biophys Sin (Shanghai); 2020 Jun; 52(6):638-653. PubMed ID: 32395755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients.
    Martínez-Terroba E; Behrens C; de Miguel FJ; Agorreta J; Monsó E; Millares L; Sainz C; Mesa-Guzman M; Pérez-Gracia JL; Lozano MD; Zulueta JJ; Pio R; Wistuba II; Montuenga LM; Pajares MJ
    J Pathol; 2018 Aug; 245(4):421-432. PubMed ID: 29756233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microarray analysis of the expression profile of immune-related gene in rapid recurrence early-stage lung adenocarcinoma.
    Liu J; Yang X; Zhang L; Yang B; Rao W; Li M; Dai N; Yang Y; Qian C; Zhang L; Xiao H; Wang D
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2299-2310. PubMed ID: 32556504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique metastasis-associated lncRNA signature optimizes prediction of tumor relapse in lung adenocarcinoma.
    Zhang X; Han J; Du L; Li X; Hao J; Wang L; Zheng G; Duan W; Xie Y; Zhao Y; Zhang X; Zou M; Wang C
    Thorac Cancer; 2020 Mar; 11(3):728-737. PubMed ID: 31994347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma.
    Song Q; Shang J; Yang Z; Zhang L; Zhang C; Chen J; Wu X
    J Transl Med; 2019 Mar; 17(1):70. PubMed ID: 30832680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of T-cell receptor and B-cell receptor repertoire on the recurrence of early stage lung adenocarcinoma.
    Liu J; Yang X; Lu X; Zhang L; Luo W; Cheng Y; Zhang L; Yang Y; Dai N; Xu Y; Guan Y; Xiao H; Li M; Wang D
    Exp Cell Res; 2020 Sep; 394(2):112134. PubMed ID: 32540399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A B7-CD28 family based signature demonstrates significantly different prognoses and tumor immune landscapes in lung adenocarcinoma.
    Zheng S; Luo X; Dong C; Zheng D; Xie J; Zhuge L; Sun Y; Chen H
    Int J Cancer; 2018 Nov; 143(10):2592-2601. PubMed ID: 30152019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spread through air spaces is an independent predictor of recurrence in stage III (N2) lung adenocarcinoma.
    Terada Y; Takahashi T; Morita S; Kashiwabara K; Nagayama K; Nitadori JI; Anraku M; Sato M; Shinozaki-Ushiku A; Nakajima J
    Interact Cardiovasc Thorac Surg; 2019 Sep; 29(3):442-448. PubMed ID: 31106332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal Growth Factor Receptor Mutation as a Risk Factor for Recurrence in Lung Adenocarcinoma.
    Hayasaka K; Shiono S; Matsumura Y; Yanagawa N; Suzuki H; Abe J; Sagawa M; Sakurada A; Katahira M; Takahashi S; Endoh M; Okada Y
    Ann Thorac Surg; 2018 Jun; 105(6):1648-1654. PubMed ID: 29486179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A P53-Deficiency Gene Signature Predicts Recurrence Risk of Patients with Early-Stage Lung Adenocarcinoma.
    Zhao Y; Varn FS; Cai G; Xiao F; Amos CI; Cheng C
    Cancer Epidemiol Biomarkers Prev; 2018 Jan; 27(1):86-95. PubMed ID: 29141854
    [No Abstract]   [Full Text] [Related]  

  • 14. Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival.
    Ujiie H; Kadota K; Chaft JE; Buitrago D; Sima CS; Lee MC; Huang J; Travis WD; Rizk NP; Rudin CM; Jones DR; Adusumilli PS
    J Clin Oncol; 2015 Sep; 33(26):2877-84. PubMed ID: 26261257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A seven-long noncoding RNA signature predicts relapse in patients with early-stage lung adenocarcinoma.
    Zhou H; Zhang H; Chen J; Cao J; Liu L; Guo C; Huang G; Zeng D
    J Cell Biochem; 2019 Sep; 120(9):15730-15739. PubMed ID: 31050375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome-Wide DNA Methylation Profiling in Early Stage I Lung Adenocarcinoma Reveals Predictive Aberrant Methylation in the Promoter Region of the Long Noncoding RNA PLUT: An Exploratory Study.
    Kim-Wanner SZ; Assenov Y; Nair MB; Weichenhan D; Benner A; Becker N; Landwehr K; Kuner R; Sültmann H; Esteller M; Koch I; Lindner M; Meister M; Thomas M; Bieg M; Klingmüller U; Schlesner M; Warth A; Brors B; Seifried E; Bönig H; Plass C; Risch A; Muley T
    J Thorac Oncol; 2020 Aug; 15(8):1338-1350. PubMed ID: 32272161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of distant recurrence in resected stage I and II lung adenocarcinoma.
    Aramini B; Casali C; Stefani A; Bettelli S; Wagner S; Sangale Z; Hughes E; Lanchbury JS; Maiorana A; Morandi U
    Lung Cancer; 2016 Nov; 101():82-87. PubMed ID: 27794412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma.
    Qian F; Yang W; Wang R; Xu J; Wang S; Zhang Y; Jin B; Yu K; Han B
    J Thorac Cardiovasc Surg; 2018 Mar; 155(3):1227-1235.e2. PubMed ID: 29223834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients.
    Kaduthanam S; Gade S; Meister M; Brase JC; Johannes M; Dienemann H; Warth A; Schnabel PA; Herth FJ; Sültmann H; Muley T; Kuner R
    Lung Cancer; 2013 May; 80(2):223-7. PubMed ID: 23410826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression signature predicts recurrence in lung adenocarcinoma.
    Larsen JE; Pavey SJ; Passmore LH; Bowman RV; Hayward NK; Fong KM
    Clin Cancer Res; 2007 May; 13(10):2946-54. PubMed ID: 17504995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.